This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

The Medicines' CEO Presents At Deutsche Bank Annual Healthcare Conference (Transcript)

The Medicines Company (MDCO)

Deutsche Bank Annual Healthcare Conference Call

May 7, 2012 2:10 pm ET

Executives

Clive A. Meanwell – Chairman and Chief Executive Officer

William B. O’Connor – Vice President and Chief Accounting Officer

Analysts

Navdeep Singh – Deutsche Bank Securities, Inc.

Presentation



Navdeep Singh – Deutsche Bank Securities, Inc.

All right. Good afternoon, everyone, and thanks for joining us in for afternoon session. My name is Navdeep Singh, and I am one of the Biotech Analyst at Deutsche Bank. And it’s my pleasure to announce our next company The Medicines Company. And presenting on behalf of The Medicines Company is Clive Meanwell, Chairman and CEO. We also have Bill O’Connor, the Chief Accounting Officer on the stage today.

And before, we start our presentation I just want to give you guys a heads up. We have this new app that we trying out, we call the [Yorn] app. The instructions to use it are on your desks. And it’s just basically, if you don’t want to ask live question, and you want me to ask it on your behalf, feel free to follow the instructions then I will ask the question on your behalf.

So with that, Clive, you want to take the podium?

Clive A. Meanwell

Thank you very much, Navdeep, and thank you to Deutsche Bank for the invitation to this conference. I was worried that [Yorn] app meant that you had to push a button and there was trap door in the stage, but hopefully, no.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 17,712.66 +34.43 0.19%
S&P 500 2,061.02 +4.87 0.24%
NASDAQ 4,891.2190 +27.8570 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs